E-ISSN: 2148-6247
PREPARATION AND IN VIVO EVALUATION OF EUDRAGIT® L100/EUDRAGIT® NM 30D ENTERIC GRANULES CONTAINING DICLOFANAC SODIUM: ANTI-INFLAMMATORY AND ULCEROGENIC ACTIVITY
PDF
Cite
Share
Request
Original Article
VOLUME: 7 ISSUE: 3
P: 237-248
December 2010

PREPARATION AND IN VIVO EVALUATION OF EUDRAGIT® L100/EUDRAGIT® NM 30D ENTERIC GRANULES CONTAINING DICLOFANAC SODIUM: ANTI-INFLAMMATORY AND ULCEROGENIC ACTIVITY

Turk J Pharm Sci 2010;7(3):237-248
Meltem ÇETİN 1
Esra Tuba DEMİR 1
Halis SÜLEYMAN 2
Elif ÇADIRCI 2
Ahmet HACIMÜFTÜOĞLU 2
Beyzagül POLAT 2
1. University Of Atatürk, Faculty Of Pharmacy, Department Of Pharmaceutical Technology, 25240 Erzurum, Turkey
2. University Of Atatürk, Faculty Of Medicine, Department Of Pharmacology, 25240 Erzurum, Turkey
No information available.
No information available
Received Date: 30.07.2009
Accepted Date: 24.12.2009
PDF
Cite
Share
Request

ABSTRACT

Extended-release granule formulations containing diclofenac sodium were prepared by wet granulation of Eudragit® LI00 and Eudragit® NM 30D polymers. The drug release was examined in phosphate buffer (pH 6.8). The formulations allowed 100 % released drug by 720 min. The granules were evaluated with respect to their anti-inflammatory and ulcerogenic activity in rats. Eudragit® LlOO/Eudragif3 NM 30D granules provide a significant and prolonged anti-inflammatory effect and also significantly reduce (52-74 %) the gastric lesion index.